{
    "name": "glucarpidase",
    "comment": "Rx",
    "other_names": [
        "Voraxaze"
    ],
    "classes": [
        "Antidotes",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/voraxaze-glucarpidase-999710",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women or animal reproduction studies to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes",
            "Therapy is administered in combination with methotrexate, which can cause embryo-fetal harm; refer to methotrexate prescribing information for additional information"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on presence of glucarpidase in human milk or effects on breastfed infant or on milk production",
            "Therapy administered in combination with methotrexate; refer to methotrexate prescribing information for additional information"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious allergic reactions (occurred in <1% of patients)",
                "Leucovorin is a substrate for glucarpidase; other potential substrates of glucarpidase include reduced folates and folate antimetabolites (eg, folic acid, L-methylfolate, pemetrexed, pralatrexate, trimethoprim, pentamidine)",
                "Immunogenicity: 17% (n=16) of patients developed anti-glucarpidase antibodies; 12 of the 16 patients had received 1 dose and the other 4 patients had received 2 doses",
                "Hypersensitivity reactions reported",
                "When measuring methotrexate concentration following a glucarpidase dose, a chromatographic method is preferred over an immunoassay"
            ],
            "specific": [
                {
                    "type": "Monitoring methotrexate serum concentrations",
                    "description": [
                        "Methotrexate concentrations within 48 hours following administration of glucarpidase can only be reliably measured by a chromatographic method",
                        "DAMPA (4-deoxy-4-amino-N10-methylpteroic acid) is an inactive metabolite of methotrexate resulting from treatment with glucarpidase that interferes with the measurement of methotrexate concentration using immunoassays (ie, immunoassays overestimates the methotrexate concentration)",
                        "Due to the long half-life of DAMPA (~9 hours), measurement of methotrexate using immunoassays is unreliable for samples collected within 48 hours following glucarpidase administration"
                    ]
                },
                {
                    "type": "Continuation and timing of leucovorin rescue",
                    "description": [
                        "Leucovorin is a substrate for glucarpidase",
                        "Do not administer leucovorin within 2 hr before or after glucarpidase",
                        "No dose adjustment is recommended for the continuing leucovorin regimen because the leucovorin dose is based on the patientâ€™s pre-glucarpidase methotrexate concentration",
                        "For the first 48 hours after glucarpidase, administer the same leucovorin dose as given prior to glucarpidase",
                        "Beyond 48 hours after glucarpidase, administer leucovorin based on the measured methotrexate concentration",
                        "Do not discontinue therapy with leucovorin based on the determination of a single methotrexate concentration below the leucovorin treatment threshold",
                        "Therapy with leucovorin should be continued until the methotrexate concentration has been maintained below the leucovorin treatment threshold for a minimum of 3 days",
                        "Continue hydration and alkalinization of the urine as indicated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "folic acid",
            "description": {
                "common": "glucarpidase will decrease the level or effect of folic acid by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "L-methylfolate",
            "description": {
                "common": "glucarpidase will decrease the level or effect of L-methylfolate by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leucovorin",
            "description": {
                "common": "glucarpidase will decrease the level or effect of leucovorin by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "glucarpidase will decrease the level or effect of pemetrexed by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "glucarpidase will decrease the level or effect of pentamidine by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "glucarpidase will decrease the level or effect of pralatrexate by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "glucarpidase will decrease the level or effect of sulfamethoxazole by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "glucarpidase will decrease the level or effect of trimethoprim by  increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Paresthesias",
            "percent": "2"
        },
        {
            "name": "Flushing",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "vomiting",
            "percent": "1"
        },
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Throat irritation",
            "percent": null
        },
        {
            "name": "throat tightness",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Antibody formation",
            "percent": null
        },
        {
            "name": "Serious hypersensitivity reactions",
            "percent": null
        }
    ]
}